- Home
- DAWN vs PAVS Comparison
DAWN vs PAVS Comparison
Compare DAWN & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- PAVS
- Stock Information
- Founded
- DAWN 2018
- PAVS 2004
- Country
- DAWN United States
- PAVS United States
- Employees
- DAWN N/A
- PAVS N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- DAWN Health Care
- PAVS Health Care
- Exchange
- DAWN Nasdaq
- PAVS Nasdaq
- Market Cap
- DAWN 624.8M
- PAVS 49.1M
- IPO Year
- DAWN 2021
- PAVS 2019
- Fundamental
- Price
- DAWN $7.11
- PAVS $0.78
- Analyst Decision
- DAWN Strong Buy
- PAVS
- Analyst Count
- DAWN 7
- PAVS 0
- Target Price
- DAWN $27.86
- PAVS N/A
- AVG Volume (30 Days)
- DAWN 960.1K
- PAVS 147.1K
- Earning Date
- DAWN 10-29-2025
- PAVS 08-04-2025
- Dividend Yield
- DAWN N/A
- PAVS N/A
- EPS Growth
- DAWN N/A
- PAVS N/A
- EPS
- DAWN N/A
- PAVS N/A
- Revenue
- DAWN $187,638,000.00
- PAVS $71,542.00
- Revenue This Year
- DAWN $12.56
- PAVS N/A
- Revenue Next Year
- DAWN $48.02
- PAVS N/A
- P/E Ratio
- DAWN N/A
- PAVS N/A
- Revenue Growth
- DAWN 2190.50
- PAVS N/A
- 52 Week Low
- DAWN $5.64
- PAVS $0.32
- 52 Week High
- DAWN $16.76
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- DAWN 51.59
- PAVS 48.43
- Support Level
- DAWN N/A
- PAVS $0.76
- Resistance Level
- DAWN $7.58
- PAVS $0.90
- Average True Range (ATR)
- DAWN 0.25
- PAVS 0.11
- MACD
- DAWN -0.32
- PAVS 0.01
- Stochastic Oscillator
- DAWN 91.92
- PAVS 26.14
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.